Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
Over 5,000 unique patients have been prescribed Ohtuvayre, with increasing refills and patient adds. Prescriber trends show a broad range of therapy combinations. Infrastructure for patient access is performing well.